Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod
Immune-mediated necrotizing myopathy (IMNM) with anti-HMGCR antibody positivity is characterized by proximal extremity weakness, increased creatine kinase, and extensive muscle edema. There is an urgent need to find more appropriate treatment options for anti-HMGCR IMNM patients who do not respond w...
Saved in:
| Main Authors: | Quantao Zeng, Kai Chen, Li Zeng, Lixia Xu, Song Tan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495415/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
by: Qiqi Peng, et al.
Published: (2025-05-01) -
Anti-HMGCR myopathy: a first case report from North Africa and literature insights
by: Houssem Abida, et al.
Published: (2025-05-01) -
Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies
by: Huang L, et al.
Published: (2024-11-01) -
Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod
by: MengTing Yang, et al.
Published: (2024-10-01) -
Treatment of refractory pemphigus vulgaris with efgartigimod
by: Matthew Helm, MD, et al.
Published: (2025-07-01)